Determining the efficacy of novel anti-androgens in models of castrate resistant prostate cancer
Currently, androgen ablation therapy for advanced prostate cancer (PCa) attempts to inactivate the androgen receptor (AR) by diminishing circulating androgen levels and/or inhibiting AR ligand-binding. Although patient response is initially positive, the cancer ultimately recurs in a more aggressive...
| Main Author: | |
|---|---|
| Published: |
University of Newcastle upon Tyne
2014
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.720010 |